Research Funding Kurma Life Science and Indinvest Participate in Research Funding

Editor: Dominik Stephan

Venture capital and private equity firms finance researches for enzymatic AKI treatments - Kumar Life Science and Indinvest agreed to enter a research funding of € 29.2 million for AM Pharma.

Related Company

(Picture: AM Pharma)
(Picture: AM Pharma)

Paris/France – Kurma Life Science Partners, a private equity firm, and venture capital company Idinvest Partners announced to enter a € 29.2 million research funding round for AM Pharma. With the money, AM Pharma, a biopharmaceutical company, aims to advance its researches on recombinant human Alkaline Phosphatase (AP) as atreatment for Acute Kidney Injury (AKI). There is currently no effective treatment for AKI, the kidney function is damaged by severe imflammation, surgery or contrast fluids. According to AM Pharma, human AP, an anti-inflammatory enzyme, shows great potentials as a medication for AKI.

Rémi Droller ,Partner at Kurma Life Science Partners, commented: “AM Pharma is a good example of the type of company we like to support. It has a strong and experienced international management team working to address unmet clinical needs with very innovative programs and it typifies our vision to channel capital to the financing of focused projects.“